Innate Immunity in Cardiovascular Diseases – Identification of Novel Molecular Players and Targets
,
,
,
,
,
,
,
Version 2 : Received: 31 October 2022 / Approved: 1 November 2022 / Online: 1 November 2022 (09:55:10 CET)
A peer-reviewed article of this Preprint also exists.
Poller, W.; Heidecker, B.; Ammirati, E.; Kuss, A.W.; Tzvetkova, A.; Poller, W.C.; Skurk, C.; Haghikia, A. Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets. Journal of Clinical Medicine 2023, 12, 335, doi:10.3390/jcm12010335. Poller, W.; Heidecker, B.; Ammirati, E.; Kuss, A.W.; Tzvetkova, A.; Poller, W.C.; Skurk, C.; Haghikia, A. Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets. Journal of Clinical Medicine 2023, 12, 335, doi:10.3390/jcm12010335.
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (1)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
Commenter: Wolfgang Poller
Commenter's Conflict of Interests: Author
This revised version contains four new figures providing in-depth overview on the basic science background of the clinical research topics addressed in the review:
Figure 2 - Cellular receptors and signaling pathways linking innate immunity with cardiovascular diseases
Figure 3 – Key features of the human noncoding genome and epigenome and suggested novel therapeutic targets therein
Figure 4 – Novel nucleic acid therapeutics targeting conventional protein-coding genes or noncoding RNA targets
Figure 5 - Cellular receptors and signaling pathways linking innate immunity with cardiovascular diseases
The review conclude with a ‘take home message‘ summarizing point-by-point the paragraph specific
and overarching messages of the review:
1 - Practice-ready affordable advanced genetic diagnostics has entered clinical practice and is continuously providing important insights not only into an individual’s genetic risk, but may also uncover new pathomechanisms suitable to individualize therapy.
2 - After decades of experimental and translational work, progress from traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases has been achieved. Insights from basic genetic research (RNA interference, antisense drugs, CRISPR-Cas) are emerging fruitful for clinical medicine.
3 - Fundamentally improved understanding of the intestinal immune system and microbiome with experimental evidence for far-reaching immune impact upon cardiovascular system and brain has triggered clinical trials evaluating the potential of microbiome modulation.
4 - The rapidly evolving field of neuroimmunology has identified novel brain – immune system interaction networks revealed at unprecedented resolution, and documented grave adverse impact of stress upon cardiovascular and virological diseases.